A Retrospective, Observational Study of RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis

Inclusion Criteria: * Adult patients, \>=18 years of age * Diagnosed with rheumatoid arthritis and moderate to severe disease activity defined as a DAS28 \>=5.1 * Inadequate responder to at least 2 non-biological DMARDs * Absence of documented erosions at start of RoActemra/Actemra treatment * Received RoActemra/Actemra treatment for at least 6 months * Availability of data from at least the RoActemra/Actemra treatment initiation visit and the 6 months visit Exclusion Criteria: * Contraindications for treatment with RoActemra/Actemra